The Board of Directors of DHH S.p.A. has examined and approved the consolidated financial statements report for the first half of 2019

Double-digit growth on revenue and positive cash generation with >80% EBITDA cash conversion rate International leadership in Southeast Europe (the so-called “Adriatic Sea area”) with 100.000+ customers and a turnover spread across 5 countries - Italy, Italian Switzerland, Slovenia, Croatia, Serbia FINANCIAL HIGHLIGHTS: - NET SALES EQUAL TO EUR 3,3 MILLION VERSUS EUR 2,9 MILLION AS OF 30 JUNE 2018 - EBITDA EQUAL TO EUR 242 THOUSAND VERSUS EUR 278 THOUSAND AS OF 30 JUNE 2018 - NET RESULT EQUAL TO EUR 31 THOUSAND VERSUS EUR 103 THOUSAND AS OF 30 JUNE 2018 - NET FINANCIAL POSITION EQUAL TO EUR 2,56 MILLION, OF WHICH: EUR 2,91 MILLION (CASH EQUIVALENT); EUR 13 THOUSAND (CURRENT FINANCIAL ASSETS); EUR 136 THOUSAND (CURRENT FINANCIAL DEBT) AND EUR 227 THOUSAND (NON-CURRENT FINANCIAL DEBT) Giandomenico Sica, Chairman of the Board of Directors of DHH, commented: “The first half of 2019 is in line with our historical trend. We were able to keep a double digit organic growth rate with 3.3M EUR of net sales in the period vs 2.9M EUR in the 1H2018. This semester was also important to consolidate the extraordinary operations that we made last year in the Balkans. As a consequence of this work, we built the operational infrastructure to prepare the group to execute new M&A deals. In these months we made an intense scouting activity, looking for new opportunities of acquisitions, bigger than the ones we made in the past. In fact, we believe that now DHH has the potential to address bigger opportunities, with the goal of making a jump in its size so to increase its market positioning in the Southeast Europe, where we are currently present with our 100.000+ customers spread across Italy, Italian Switzerland, Slovenia, Croatia, Serbia.”
Protocollo
68120
Comunicato
Azienda
DHH
Tipo
Comunicato
SDIR
SDIRNIS
Lingua
ENG
Data creazione
Data ricezione SDIR
Data embargo SDIR
Data diffusione SDIR
Mercato
Euronext Growth Milan